Patents by Inventor Andrew Michael Lindsay Lever

Andrew Michael Lindsay Lever has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Chimaeric vector system
    Patent number: 8298826
    Abstract: This invention relates to a process for producing a Simian Immunodeficiency Virus (SIV) encoding a heterologous gene, which process comprises infecting a host cell with a first vector which is capable of producing SIV capsid and a second vector comprising a Human Immunodeficiency Virus type 2 (HIV-2) packaging signal sufficient to package the second vector in the SIV capsid and a heterologous gene capable of being expressed by the vector; and culturing the host cell.
    Type: Grant
    Filed: August 9, 2004
    Date of Patent: October 30, 2012
    Assignee: Cambridge Enterprise Limited
    Inventors: Andrew Michael Lindsay Lever, Padraig Michael Strappe
  • Compositions comprising a tissue glue and therapeutic agents
    Patent number: 6919067
    Abstract: The present invention concerns compositions comprising a radiotherapeutic agent, or an agent which can be converted to a radiotherapeutic, and a tissue glue. The compositions of the present invention are particularly useful for providing local radiotherapy. The present invention also concerns methods of using the compositions of the invention, particularly for radiotherapy.
    Type: Grant
    Filed: December 11, 2001
    Date of Patent: July 19, 2005
    Assignee: Syngenix Limited
    Inventors: Aaron Gershon Filler, Andrew Michael Lindsay Lever
  • Synthetic transfection vectors
    Patent number: 6809082
    Abstract: An inorganic particle, to which is bonded a cell binding component and a nucleic acid, is provided for delivery of a nucleic acid to a cell. The disclosed particle acts as a synthetic vector for achieving efficient transfection of associated nucleic acid into a cell.
    Type: Grant
    Filed: October 4, 2001
    Date of Patent: October 26, 2004
    Assignee: Molecular Synthetics, Ltd.
    Inventors: Aaron Gershon Filler, Andrew Michael Lindsay Lever
  • Compositions comprising a tissue glue and therapeutic agents
    Publication number: 20020168319
    Abstract: The present invention concerns compositions comprising a radiotherapeutic agent, or an agent which can be converted to a radiotherapeutic, and a tissue glue. The compositions of the present invention are particularly useful for providing local radiotherapy. The present invention also concerns methods of using the compositions of the invention, particularly for radiotherapy.
    Type: Application
    Filed: December 11, 2001
    Publication date: November 14, 2002
    Inventors: Aaron Gershon Filler, Andrew Michael Lindsay Lever
  • Synthetic transfection vectors
    Publication number: 20020123478
    Abstract: An inorganic particle, to which is bonded a cell binding component and a nucleic acid, is provided for delivery of a nucleic acid to a cell. The disclosed particle acts as a synthetic vector for achieving efficient transfection of associated nucleic acid into a cell.
    Type: Application
    Filed: October 4, 2001
    Publication date: September 5, 2002
    Inventors: Aaron Gershon Filler, Andrew Michael Lindsay Lever
  • Defective packaging non-oncoviral vectors based on HIV
    Patent number: 6294165
    Abstract: Novel vectors are capable of producing MPMV (Mason-Pfizer Monkey Virus) proteins but not of packaging MPMV RNA, and the information about the packaging signal in MPMV and HIV can be used to create MPMV and HIV vectors that are capable of transferring foreign genes, e.g. for use in gene therapy.
    Type: Grant
    Filed: December 18, 1997
    Date of Patent: September 25, 2001
    Assignee: Syngenix, Ltd.
    Inventors: Andrew Michael Lindsay Lever, Eric Hunter
  • Synthetic transfection vectors
    Patent number: 6153598
    Abstract: An inorganic particle, to which is bonded a cell binding component and a nucleic acid, is provided for delivery of a nucleic acid to a cell. The disclosed particle acts as a synthetic vector for achieving efficient transfection of associated nucleic acid into a cell.
    Type: Grant
    Filed: April 17, 1998
    Date of Patent: November 28, 2000
    Assignee: Syngenix Limited
    Inventors: Aaron Gershon Filler, Andrew Michael Lindsay Lever
  • Mason-Pfizer Monkey Retroviral packaging defective vectors
    Patent number: 5747307
    Abstract: Novel vectors are capable of producing MPMV (Mason-Pfizer Monkey Virus) proteins but not of packaging MPMV RNA, and the information about the packaging signal in MPMV and HIV can be used to create MPMV and HIV vectors that are capable of transferring foreign genes, e.g. for use in gene therapy.
    Type: Grant
    Filed: August 26, 1994
    Date of Patent: May 5, 1998
    Assignee: Syngenix Limited
    Inventors: Andrew Michael Lindsay Lever, Eric Hunter